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Abstract
Objective—To compare the effects of true and sham acupuncture in relieving symptoms of IBS.
Methods—A total of 230 adult IBS patients (75% females, average age 38.4 yrs) were randomly
assigned to 3 weeks of true or sham acupuncture (6 treatments) following a 3 week ‘run-in’ with
sham acupuncture in an ‘augmented’ or ‘limited’ patient-practitioner interaction. A third arm of the
study included a waitlist control group. The primary outcome was the IBS Global Improvement Scale
(IBS-GIS) (range 1–7); secondary outcomes included IBS Symptom Severity Scale (IBS-SSS),
Adequate Relief (IBS-AR) and IBS-Quality of life (IBS-QOL).
Results—Though there was no statistically significant difference between acupuncture and sham
acupuncture on the IBS-GIS (41% vs. 32%, p=0.25), both groups improved significantly compared
to the wait list control group (37% vs. 4%, p=0.001). Similarly, small differences that were not
statistically significant favored acupuncture on the other three outcomes: IBS-AR (59% vs 57%,
p=0.83), IBS-SSS (31% vs 21%, p=0.18) and IBS-QOL (17% vs 13%, p=0.56). Eliminating
responders during the run-in period did not substantively change the results. Side effects were
generally mild and only slightly greater in the acupuncture group.
Conclusion—This study did not find evidence to support the superiority of acupuncture compared
to sham acupuncture in the treatment of IBS.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by
chronic or recurrent abdominal pain or discomfort, usually in the lower abdomen, which is
associated with disturbed bowel function and feelings of abdominal distention and bloating
1 that are often relieved by defecation. An estimated 10–15% of adults in North America suffer
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from IBS 2, and it is associated with a significant reduction in health related quality of life 3.
IBS is one of the most common reasons for work and school absenteeism 4. Estimates of annual
direct and indirect costs associated with IBS exceed 41 billion dollars in major industrial
countries 5.
The pathophysiology of IBS includes alterations in intestinal motility, visceral hypersensitivity
and abnormalities in the processing of visceral information. Until recently, most therapies for
IBS have been directed at a specific intestinal symptom (e.g., diarrhea, constipation, or
abdominal pain) and have not been effective for treating other symptoms associated with IBS.
While more recent therapies have shown promise, treatment options for IBS remain limited.
Therefore, it is not surprising that many patients with IBS have turned to complementary and
alternative medicine (CAM) 6 such as acupuncture. In one survey, approximately one half of
subjects with IBS reported using CAM 7.
Acupuncture, an ancient traditional Chinese medical practice, is becoming more widely
accepted and used in Western society 8. Traditional Chinese medicine is based on a theory of
energy or life force (“qi”) that runs through the body in channels called meridians. Qi is essential
to health, and disruptions of this flow, which are believed to contribute to symptoms and
diseases, can be corrected at identifiable anatomical locations (“acupoints”) with acupuncture.
In IBS, acupuncture is believed to alter visceral sensation and motility by stimulating the
somatic nervous system and the vagus nerve 9–11.
A 2006 Cochrane Database article reviewed 6 randomized trials using acupuncture in IBS12.
The studies were generally of poor quality, included relatively small numbers of patients, and
differed significantly in acupuncture method utilized. Limitations notwithstanding, this review
found inconclusive evidence as to whether acupuncture is superior to sham acupuncture in IBS.
Subsequently, Schneider et al. 13 published the results of a well conducted study in which 43
IBS patients were randomized to acupuncture or sham acupuncture. There was no significant
difference between the response rates in patients receiving acupuncture and sham acupuncture
on a specific quality of life measurement for functional bowel digestive disorders (FBDDQL)
14 although patients in both groups improved significantly compared to baseline.
Our study comparing acupuncture to sham acupuncture was nested within a larger study
examining the impact of the patient-practitioner interaction in IBS patients. In this larger study,
which served as the run-in period for our study, participants were randomized to three weeks
of: 1) waitlist, 2) sham acupuncture (twice a week) with a ‘limited’ patient-practitioner
encounter, or 3) sham acupuncture (twice a week) with an ‘augmented’ patient-practitioner
encounter (i.e, a warm, friendly, and supportive patient-practitioner interaction). The results
of this three-week run-in are reported elsewhere 15. After three weeks, participants receiving
sham acupuncture were seamlessly and unknowingly re-randomized to continue for another
three weeks on either acupuncture or sham acupuncture with the same ‘limited’ or ‘augmented’
patient-practitioner encounter that they had received during the run-in phase of the trial. This
second three week period comprises the acupuncture study reported here.
The aims of this trial were threefold: 1) to determine if acupuncture provides greater relief of
IBS symptoms than sham acupuncture or waitlist control, 2), to determine if eliminating
patients who responded to sham acupuncture during the run-in period (i.e., patients who
responded to sham acupuncture during the 3 weeks prior to randomization to acupuncture or
sham acupuncture) widens the response rate differences between acupuncture and sham
acupuncture, perhaps to the point of statistical significance, and 3) to determine if an
‘augmented’ patient-practitioner interaction enhances the difference in response rates between
acupuncture and sham acupuncture.
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In the larger trial 262 IBS-patients were randomized to a 3 week run-in of either: 1) waitlist
(observation), 2) sham acupuncture (2 sessions per week) with a ‘limited’ patient-practitioner
encounter, or 3) sham acupuncture (2 sessions per week) with an ‘augmented’ patient-
practitioner encounter (i.e, a warm, friendly, and supportive patient-practitioner relationship).
The larger study explored the effects of placebo and patient-practitioner relationship in IBS
and is reported elsewhere 16.
For this study, at the end of week 3 patients who had received sham acupuncture were blindly
re-randomized to either acupuncture or continuation of sham acupuncture. This randomization
was stratified by the group assignment for the run-in period (augmented versus limited) and
by the post run-in pain score (under 30 versus 30 or over on a 100-point visual analog scale).
Patients continued with the same ’limited’ or augmented‘ patient-practitioner interaction that
they had received during the first 3 weeks of the study. Patients were unaware that only sham
acupuncture had been administered during the run-in phase of this study and similarly were
unaware of the existence of different patient-practitioner interactions. Patients who were
initially in the waitlist control group continued on in this group. Figure 1 reviews the flow of
patients through this study.
Treatment and study assessments were performed at the Beth Israel Deaconess Medical
Center’s General Clinical Research Center (GCRC). The Institutional Review Boards at the
Beth Israel Deaconess Medical Center and Harvard Medical School approved the design and
all participants provided informed consent.
Subjects—Participants were recruited from advertisements in media, fliers, and referrals
from health professionals 17. All subjects were at least 18 years old and met the Rome II criteria
for IBS 18 . In addition, the diagnosis of IBS was confirmed by a board certified
gastroenterologist experienced in functional bowel disorders (AJL) who also assessed for
‘warning symptoms’ (unexplained weight loss, family history of colon cancer or inflammatory
bowel disease, and rectal bleeding) 19, 20. Participants were allowed to continue their IBS
medications (e.g., fiber, anti-spasmodics, loperamide) as long as they had been on stable doses
for at least 30 days prior to entering the study and agreed not to change medications or dosages
during the trial. Patients were also asked not to make significant changes to their diet during
the study. Patients were excluded if they had previously received acupuncture, if they had
abdominal surgery (excluding cholecystectomy, appendectomy, hysterectomy, hernia repair),
or if they were on narcotics or other pain medications (except non-steroidal anti-inflammatory
drugs).
Interventions
Acupuncture—For this study we used a manualized acupuncture protocol that combined a
fixed number of always used acupuncture points and a menu of optional points that could be
applied based on the participant’s Chinese medicine diagnosis 21. This method allows for
reproducibility and also the flexibility that many acupuncturists claim is critical for their
practice. Accordingly, we chose 6 main fixed acupoints and 11 optional points, which could
be selected based on a traditional Chinese acupuncture diagnosis of the individual patient by
the acupuncturist. This regimen was developed by a consensus team of eight senior
acupuncturists, each with over 15 years of experience. The fixed points are very commonly
used in IBS patients and included: Conception Vessel 10, Stomach 25, Liver 3, Spleen 4,
Pericardium 6 and Stomach 37. The optional points were Stomach 36 and Conception Vessel
4 (for the Chinese diagnosis of deficiency), Large Intestine 4 Liver 14, (for stagnant qi or
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energy), Stomach 40, Large Intestine 11 (for dampness), Stomach 27 (for cold), Conception
Vessel 12 (for “retention of food”), Gall Bladder 34 (for “damp heat”) and Spleen 10 and Spleen
6 (for “blood stasis”). The optional points were extensively discussed by the acupuncture team
and were selected based by a shared understanding of Chinese medicine differential diagnosis.
If the acupuncturist felt strongly that a fixed main point would be less desirable than an optimal
point, they were allowed to replace a single fixed point with an optional point. The sensation
of grasping the energy ( “de qi”) was obtained and the needles were left in place for twenty
minutes 22. Acupuncture treatment procedures were reviewed in regular team meetings.
Sham Acupuncture—In this study we used Streitberger needles 23, a validated sham
acupuncture device. This device has been shown to be indistinguishable from an actual
acupuncture device; the ‘needle’ does not pierce the skin but creates the illusion of doing so
as it retracts into a hollow handle. Streitberger and true acupuncture needles were applied for
an identical period of time. To avoid acupuncture pressure effect, sham needles were placed
over predetermined ‘non-acupuncture’ points in the relative vicinity of the genuine points. Our
team’s precise method of using the sham needles is extensively described elsewhere 24.
During the placebo run-in phase, acupuncturists were instructed to select at least five and a
maximum of eleven ‘non-acupuncture’ points as if they were actually performing a genuine
points. They were also encouraged to slightly switch or adjust their point selection within the
parameters of the study protocol from treatment to treatment (which is what would usually
happen regular practice). These maneuvers were done in order that patients who were
randomized to genuine acupuncture would experience identical procedures in terms of number
of needles and the attention of the acupuncturists when switched from placebo to genuine
treatment. Of course, patients were entirely blind to the run-in phase of the trial and were
unaware of any change from sham to genuine treatment in the protocol.
Practitioners—Four licensed acupuncturists, each with over 2,000 hours of professional
training and over four years of post-graduate experience, performed the acupuncture in this
study. The method used for their training and supervision is described elsewhere 25. Before
the study began, all acupuncturists agreed that the therapeutic intervention they were to perform
was an effective form of acupuncture.
Patient-Practitioner Interaction—Patients continued to receive the same patient-
practitioner interaction (i.e., ‘limited’ or ‘augmented’ relationship) as they had received in the
initial three-week run-in. The details of the two scripted patient-practitioner interactions are
reported elsewhere 16. The random assignment of interactions across treatment arms allowed
for a secondary comparison of acupuncture versus sham acupuncture, each with two different
styles of patient-practitioner interaction without compromising the outcome of our primary
study objective.
Outcome Measures
Primary Outcome—The a priori primary endpoint of the study was the Global Improvement
Scale (IBS-GIS) that asked participants: “Compared to the way you felt before you entered the
study, have your IBS symptoms over the past 7 days been: 1) “Substantially Worse”,
2)”Moderately Worse, 3)”Slightly Worse”, 4)”No Change”, 5)”Slightly Improved”,
6)”Moderately Improved” or 7) “Substantially Improved” 26, 27. A responder was defined as
a patient who answered either “moderately improved” or “substantially improved” to the
foregoing question.
Lembo et al. Page 4













Secondary Outcomes—Secondary outcomes measured in this study were IBS Adequate
Relief (IBS-AR) 28, 29, IBS Symptom Severity Scale (IBS-SSS) 30, and IBS Quality of Life
Scale (IBS-QOL) 31, 32.
IBS Adequate Relief: IBS-AR is a dichotomous single item that asks participants “Over the
past week have you had adequate relief of your IBS symptoms?” This type of outcome has
been used extensively to assess efficacy in IBS clinical trials 33, 34 and has been shown to
correlate with improvement in individual IBS symptoms 28. A responder was defined as a
patient who answered this question affirmatively.
IBS Symptom Severity Scale: The IBS-SSS contains five questions that are rated on a 100-
point visual analogue scale (VAS): the severity of abdominal pain, the frequency of abdominal
pain, the severity of abdominal distention, dissatisfaction with bowel habits, and interference
with quality of life 30. All five components contribute to the score equally yielding a theoretical
range of 0–500, with a higher score indicating a worse condition. Previous studies have
established that scores below 175 represent mild IBS symptoms, 175–300 represents moderate
severity, and scores above 300 represent severe IBS 30. A decrease of 50 points on the IBS-
SSS has been shown to correlate with improvement in clinical symptoms. We, therefore,
defined patients with a decrease of 50 points or more on the IBS-SSS as responders in this
study.
IBS-Quality of Life: The IBS-QOL is a 34-item measure assessing the degree to which IBS
interferes with patient’s quality of life. Each item is rated on a 5-point Likert scale and all items
are summed. The total score is then converted linearly to a 100 point scale, with higher scores
indicating improved quality of life 35.. In accordance with a study by Drossman et al., we
defined responders as patients whose IBS-QOL scores improved by 10 points or more from
baseline 36.
STATISTICAL ANALYSIS
For the primary endpoint, our sample size afforded 80% power to detect a percentage point
difference in responder rates. Chi square tests of independence were used to determine whether
significant differences existed between groups in the proportion of responders. In addition,
where possible (i.e., for continuous measures), we also used parametric statistics (t-tests and
ANOVA) because of the potential for improved power. All analyses were intent-to-treat, using
the last observation carried forward (LOCF) method. For clarity, we report here only non-
parametric analyses for dichotomous outcomes (i.e., responder vs. non-responder). Except
where noted in the text, parametric tests yielded similar results. All tests were two-tailed with
alpha set at .05.
RESULTS
Patient Characteristics
Between December 2003 and February 2006, we screened 350 prospective participants and
enrolled 262 into the study. Of the 262 potential patients, 32 patients (5 in the ‘augmented’
arm; 17 in the ‘limited’ arm; and 10 in the waitlist arm) discontinued the trial during the first
three weeks (i.e., prior to randomization between acupuncture and sham acupuncture). Thus,
230 patients entered into the study reported here. Table 1 displays these patient characteristics
by treatment group.
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Acupuncture vs Sham Acupuncture
On the IBS-GIS 41% of patients who received acupuncture were responders (i.e., ‘moderate’
or ‘substantial’ improvement in their IBS symptoms during the preceding week), while 32%
of patients who received sham acupuncture were responders (p=0.25). Although more of the
acupuncture recipients were responders than sham acupuncture recipients, the difference was
not statistically significant (p=0.25) (Figure 2). Similar non-statistically significant differences
were seen in the responder rates for IBS-AR, IBS-QOL and IBS-SSS (Figure 2).
We had hoped that removing patients who responded to sham acupuncture during the 3 week
run-in phase of the trial would diminish the response rate to sham acupuncture during the
second 3 week phase of the trial and, therefore, widen the gap between acupuncture responders
and sham acupuncture responders. However, contrary to our expectations, the gap between
acupuncture responders and sham acupuncture responders narrowed for our primary outcome
measure the IBS-GIS (24% vs. 25%, p=0. 96). Similarly, removing responders for the each of
the secondary endpoints at the end of the run-in phase also did not yield statistically significant
differences between acupuncture and sham acupuncture in the IBS-AR (33% vs 24%, p=.42),
IBS-SSS (36% vs 21%, p=0.20) and IBS-QOL (18% vs. 11% p =0.53).
Acupuncture and Sham Acupuncture vs. Waitlist Control
Patients receiving acupuncture or sham acupuncture were more likely to be responders on the
IBS-GIS than patients in the waitlist control group (37% vs. 4%, p<.001) (Figure 2). Likewise,
patients receiving acupuncture or sham acupuncture versus those on the waitlist control were
significantly more likely to be responders on the IBS-AR (58% vs. 35%, p<.001) and IBS-SSS
(26% vs. 14%, p=.04). There was a numerical but not a significant difference for IBS-QOL
(15% vs. 12%, p=.49) between those receiving acupuncture or sham acupuncture versus
waitlist control.
Effect of Patient-Practitioner Interaction on Response Rates
For the IBS-GIS in both a limited and an augmented patient-practitioner interaction,
acupuncture showed a slight, non statistically significant superiority to sham acupuncture
(Table 2). Since the difference in response rates between augmented acupuncture and
augmented sham acupuncture and between limited acupuncture and limited sham acupuncture
is similar, the interaction in which acupuncture is delivered does not appear to affect its
superiority over sham acupuncture. Similar results were seen for the secondary endpoints with
the exception of the IBS-QOL in the ‘limited’ acupuncture arm.
Adverse Events
Three adverse events were reported during the acupuncture vs sham acupuncture phase of the
study: 1) painful foot cramp following treatment (sham acupuncture), 2) nausea/hip pain (true
acupuncture), and 3) rib pain after a fall (sham acupuncture). All of the events were considered
to be unrelated to the study procedure.
Discussion
Our study is the largest RCT with acupuncture to be performed in IBS. Our results demonstrated
that acupuncture and sham acupuncture are not significantly different in improving the
symptoms of IBS, although both treatments are significantly better than no treatment (i.e.,
waitlist). Eliminating responders in the run-in phase of the study in which patients received
only sham acupuncture had no substantive effect on the outcome. Finally, the context of the
patient-practitioner interaction (i.e., a warm friendly and supportive relationship (‘augmented’)
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or a neutral (‘limited’) relationship) also did not modify the difference in responder rates
between acupuncture and sham acupuncture.
Our findings are consistent with the majority of trials of acupuncture in IBS included in the
recent Cochrane Database Review 12 and the subsequent study by Schneider and colleagues
13 from Germany. Like our trial, the German study found a numerically small superiority of
improvement in patients receiving acupuncture compared to patients receiving sham
acupuncture. The German study included 43 patients and estimated that if acupuncture had
efficacy beyond placebo the number of patients needed to adequately power such a study to
be 566; we found the number of patients needed to adequately power such a study to be
approximately 970. Importantly, in contrast to the study by Schneider and colleagues 13, which
did not have a waitlist control (or standard of care) arm, our study found response rates in
patients receiving acupuncture and sham acupuncture to be superior to that of patients in a
waitlist control. This demonstrates unequivocally that symptom improvement was not the
result of natural history or regression to the mean. Our findings are consistent with the results
of recent large German acupuncture trials for other illnesses, such as chronic low back pain
37, tension-type headache 38, migraine 39, 40, and osteoarthritis of the knee 41 in which
acupuncture and sham acupuncture were not different in efficacy but both were superior to no
treatment or standard of care. In April 2006, the German health authorities decided to reimburse
for acupuncture for low back pain and osteoarthritis of the knee (but not for headache or other
types of osteoarthritis) based on the beneficial effects over no treatment or standard of care
and its potential cost savings 42–44.
We had hoped that removing patients who had responded to sham acupuncture during the 3
week run-in phase of the trial would diminish the response rate to sham acupuncture during
the second 3 week phase of the trial and, therefore, widen the gap between acupuncture
responders and sham acupuncture responders. However, our results do not show a widening
of the gap. In fact, contrary to expectations, the difference between acupuncture responders
and sham acupuncture responders actually narrowed for our primary outcome measure (IBS-
GIS) and the IBS-SSS. Our findings support other studies that have also failed to find increased
efficiency in detecting intervention-placebo differences with the removal of placebo
responders during a run-in phase 45, 46.
Our study had several limitations. First, 6 treatments of acupuncture over 3 weeks may have
been insufficient to achieve maximum effect from acupuncture. Second, this study was nested
in a larger study designed to evaluate the effects of patient-practitioner interaction in IBS. Thus,
a run-in phase occurred prior to randomization between acupuncture and sham acupuncture,
which had a significant drop-out rate and thereby decreased the power of our study. Also, some
might object to our manualized approach to acupuncture treatment and argue for either a full
standardized protocol or a totally flexible protocol. We feel that our manualized procedure is
as close to actual clinical practice as reproducibility will allow. Last, there is debate in the
acupuncture literature if sham acupuncture, although indistinguishable from acupuncture, is
indeed ineffective. The mechanism of acupuncture is unknown and sham acupuncture may be
a less effective form of acupuncture 47.
In summary, although our study failed to show a statistically significant superiority of
acupuncture over sham acupuncture in the treatment of IBS, patients receiving both
acupuncture and sham acupuncture improved significantly compared to waitlist control.
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Figure 1. Flow of Patients through the Study
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Figure 2. Percent of Patients who were Responders by Outcome Measure
Note. Error bars indicate standard errors. None of the acupuncture-sham acupuncture
differences are statistically significant.
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Table 1
Demographics and Baseline Symptoms
Acupuncture (N=78) Sham Acupuncture (N=75) Waitlist (N=77)
Demographics
  Mean Age (SD) 37.5 (14.6) 38.9 (14.1) 39.0 (14.0)
  Female 78 77 74
  Caucasian 84 89 90
  Married/Living Together 47 43 39
  Graduated College 73 77 78
  Employed 78 81 81
IBS Type and Duration
  Constipation 22 15 27
  Diarrhea 21 32 24
  Alternating 57 53 49
  IBS for > 1 year 96 91 95
Baseline IBS Symtoms
  Mean IBS-SSS (SD) 199.3 (98.3) 200.5 (83.4) 240.3 (76.0)
  Mean IBS-QOL (SD) 70.8 (17.3) 72.4 (17.6) 66.4 (17.3)
Psychiatric Symptoms
  Mean Anxiety (SD) 11.8 (9.0) 13.2 (9.3) 11.4 (9.9)
  Mean Depression (SD) 3.5 (3.4) 3.9 (3.8) 3.5 (3.6)
Note. All values are percentages except where noted.
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